287 related articles for article (PubMed ID: 25977117)
1. Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis.
VanWagner LB; Lapin B; Skaro AI; Lloyd-Jones DM; Rinella ME
Liver Int; 2015 Dec; 35(12):2575-83. PubMed ID: 25977117
[TBL] [Abstract][Full Text] [Related]
2. Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis.
Castelló B; Aguilera V; Blázquez MT; Rubín Á; García M; Vinaixa C; Benlloch S; SanJuan F; Montalva E; López R; Berenguer M
Ann Hepatol; 2019; 18(6):855-861. PubMed ID: 31543468
[TBL] [Abstract][Full Text] [Related]
3. Frequency of Cardiovascular Events and Effect on Survival in Liver Transplant Recipients for Cirrhosis Due to Alcoholic or Nonalcoholic Steatohepatitis.
Piazza NA; Singal AK
Exp Clin Transplant; 2016 Feb; 14(1):79-85. PubMed ID: 26581602
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular mortality among liver transplant recipients with nonalcoholic steatohepatitis in the United States-a retrospective study.
Satapathy SK; Jiang Y; Eason JD; Kedia SK; Wong E; Singal AK; Tolley EA; Hathaway D; Nair S; Vanatta JM
Transpl Int; 2017 Oct; 30(10):1051-1060. PubMed ID: 28622441
[TBL] [Abstract][Full Text] [Related]
5. Increased Risk of Death in First Year After Liver Transplantation Among Patients With Nonalcoholic Steatohepatitis vs Liver Disease of Other Etiologies.
Nagai S; Collins K; Chau LC; Safwan M; Rizzari M; Yoshida A; Abouljoud MS; Moonka D
Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2759-2768.e5. PubMed ID: 31004758
[TBL] [Abstract][Full Text] [Related]
6. Liver transplantation for NASH cirrhosis is not performed at the expense of major post-operative morbidity.
van den Berg EH; Douwes RM; de Meijer VE; Schreuder TCMA; Blokzijl H
Dig Liver Dis; 2018 Jan; 50(1):68-75. PubMed ID: 28935188
[TBL] [Abstract][Full Text] [Related]
7. Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016.
Golabi P; Bush H; Stepanova M; Locklear CT; Jacobson IM; Mishra A; Trimble G; Erario M; Venkatesan C; Younossi I; Goodman Z; Younossi ZM
Medicine (Baltimore); 2018 Aug; 97(31):e11518. PubMed ID: 30075518
[TBL] [Abstract][Full Text] [Related]
8. Impact of Nonmalignant Portal Vein Thrombosis in Transplant Recipients With Nonalcoholic Steatohepatitis.
Agbim U; Jiang Y; Kedia SK; Singal AK; Ahmed A; Bhamidimarri KR; Bernstein DE; Harrison SA; Younossi ZM; Satapathy SK
Liver Transpl; 2019 Jan; 25(1):68-78. PubMed ID: 30091296
[TBL] [Abstract][Full Text] [Related]
9. Non-alcoholic fatty liver disease after liver transplantation in patients with non-alcoholic steatohepatitis and cryptogenic cirrhosis: the impact of pre-transplant graft steatosis.
Eshraghian A; Nikeghbalian S; Kazemi K; Shamsaeefar A; Geramizadeh B; Malek-Hosseini SA
HPB (Oxford); 2020 Apr; 22(4):521-528. PubMed ID: 31431413
[TBL] [Abstract][Full Text] [Related]
10. Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis.
Stepanova M; Henry L; Garg R; Kalwaney S; Saab S; Younossi Z
BMC Gastroenterol; 2015 Dec; 15():175. PubMed ID: 26666336
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study.
Haldar D; Kern B; Hodson J; Armstrong MJ; Adam R; Berlakovich G; Fritz J; Feurstein B; Popp W; Karam V; Muiesan P; O'Grady J; Jamieson N; Wigmore SJ; Pirenne J; Malek-Hosseini SA; Hidalgo E; Tokat Y; Paul A; Pratschke J; Bartels M; Trunecka P; Settmacher U; Pinzani M; Duvoux C; Newsome PN; Schneeberger S;
J Hepatol; 2019 Aug; 71(2):313-322. PubMed ID: 31071367
[TBL] [Abstract][Full Text] [Related]
12. Association of Pretransplant Renal Function With Liver Graft and Patient Survival After Liver Transplantation in Patients With Nonalcoholic Steatohepatitis.
Molnar MZ; Joglekar K; Jiang Y; Cholankeril G; Abdul MKM; Kedia S; Gonzalez HC; Ahmed A; Singal A; Bhamidimarri KR; Aithal GP; Duseja A; Wong VW; Gulnare A; Puri P; Nair S; Eason JD; Satapathy SK;
Liver Transpl; 2019 Mar; 25(3):399-410. PubMed ID: 30369023
[TBL] [Abstract][Full Text] [Related]
13. Evidence of bias during liver transplant evaluation of non-alcoholic steatohepatitis cirrhosis patients.
Danford CJ; Iriana S; Shen C; Curry MP; Lai M
Liver Int; 2019 Jun; 39(6):1165-1173. PubMed ID: 30809932
[TBL] [Abstract][Full Text] [Related]
14. Waiting List Mortality and Transplant Rates for NASH Cirrhosis When Compared With Cryptogenic, Alcoholic, or AIH Cirrhosis.
Thuluvath PJ; Hanish S; Savva Y
Transplantation; 2019 Jan; 103(1):113-121. PubMed ID: 29985186
[TBL] [Abstract][Full Text] [Related]
15. Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation.
Lonardo A; Mantovani A; Petta S; Carraro A; Byrne CD; Targher G
Nat Rev Endocrinol; 2022 Oct; 18(10):638-650. PubMed ID: 35840803
[TBL] [Abstract][Full Text] [Related]
16. High early cardiovascular mortality after liver transplantation.
VanWagner LB; Lapin B; Levitsky J; Wilkins JT; Abecassis MM; Skaro AI; Lloyd-Jones DM
Liver Transpl; 2014 Nov; 20(11):1306-16. PubMed ID: 25044256
[TBL] [Abstract][Full Text] [Related]
17. Reduced impact of renal failure on the outcome of patients with alcoholic liver disease undergoing liver transplantation.
Cheong J; Galanko JA; Arora S; Cabezas J; Ndugga NJ; Lucey MR; Hayashi PH; Barritt AS; Bataller R
Liver Int; 2017 Feb; 37(2):290-298. PubMed ID: 27258535
[TBL] [Abstract][Full Text] [Related]
18. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
19. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.
Goldberg D; Ditah IC; Saeian K; Lalehzari M; Aronsohn A; Gorospe EC; Charlton M
Gastroenterology; 2017 Apr; 152(5):1090-1099.e1. PubMed ID: 28088461
[TBL] [Abstract][Full Text] [Related]
20. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
